Through IHC experiments we demonstrated that hERG1 is overexpressed in primary BC and correlates with clinicopathological parameters such as molecular subtype, grading, ER, and ki67 expression (Lastraioli et al., submitted to Br J Cancer).
The analysis was adjusted for differences in breast cancer molecular subtype, histological grade, tumor size, and nodal status.
The association between patient ordering, molecular subtype and grade was determined using a Krusal-Wallis rank sum test.
Figures 1, 2 and 3 show the impact of molecular subtype, histological grade and pathological tumor size, respectively, on overall and distant metastasis-free survival in the subgroup of node-negative patients aged less than 40 years.
Adjustment for age had no impact on the results, and adjustment for stage only slightly attenuated risk estimates.> -wrap-foot> hazardaratiotio, CI confidence interval aConditional on surviving the first 5 years Table�� 5 shows risk of death from breast cancer the first 5 years after diagnosis according to molecular subtype for grade 2 and 3.
Table 4 shows risk of death from breast cancer according to molecular subtype and histopathological grade.
From 5 years after time of diagnosis until the end of follow-up, there appears to be no difference in survival according to molecular subtype or histopathological grade.
The third molecular subtype of lower-grade gliomas had wild-type IDH and displayed a range of genetic alterations completely distinct from those of IDH-mutant lower-grade gliomas (Fig. 1).
MYCN overexpression among DGs and TGCTs is of interest due to the function of the MYCN oncogene as a positive regulator of LIN28B (323), whereas deregulation of MYCN, LIN28B, and LET7 is associated with a molecular subtype of high-grade serous ovarian cancer (324).
Similar associations with grade, molecular subtype and proliferation were observed for the host gene PPARGC1B within our patient cohort.
